AR121961A1 - Inmunoterapia con citocina - Google Patents

Inmunoterapia con citocina

Info

Publication number
AR121961A1
AR121961A1 ARP210101153A ARP210101153A AR121961A1 AR 121961 A1 AR121961 A1 AR 121961A1 AR P210101153 A ARP210101153 A AR P210101153A AR P210101153 A ARP210101153 A AR P210101153A AR 121961 A1 AR121961 A1 AR 121961A1
Authority
AR
Argentina
Prior art keywords
cytocin
immunotherapy
alphavirus
cytosine
polypeptide
Prior art date
Application number
ARP210101153A
Other languages
English (en)
Inventor
Wataru Akahata
Jonathan F Smith
Original Assignee
Vlp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlp Therapeutics Inc filed Critical Vlp Therapeutics Inc
Publication of AR121961A1 publication Critical patent/AR121961A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente memoria se proporciona un nuevo vector replicón de alfavirus inmunológicamente activo que comprende un ácido nucleico que codifica las proteínas no estructurales de alfavirus nsp1-4 y una proteína / polipéptido de citosina, que es útil para el tratamiento de un cáncer y/o una enfermedad inflamatoria.
ARP210101153A 2020-04-30 2021-04-29 Inmunoterapia con citocina AR121961A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063017993P 2020-04-30 2020-04-30

Publications (1)

Publication Number Publication Date
AR121961A1 true AR121961A1 (es) 2022-07-27

Family

ID=78292585

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101153A AR121961A1 (es) 2020-04-30 2021-04-29 Inmunoterapia con citocina

Country Status (13)

Country Link
US (1) US20210340567A1 (es)
EP (1) EP4143323A1 (es)
JP (1) JP2023524055A (es)
KR (1) KR20230005883A (es)
CN (1) CN115552009A (es)
AR (1) AR121961A1 (es)
AU (1) AU2021264216A1 (es)
BR (1) BR112022021828A2 (es)
CA (1) CA3174651A1 (es)
IL (1) IL297564A (es)
MX (1) MX2022013638A (es)
TW (1) TW202206448A (es)
WO (1) WO2021221127A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086619A2 (en) * 2022-10-19 2024-04-25 Kalivir Immunotherapeutics, Inc. Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
EP3197911A4 (en) * 2014-09-22 2018-06-20 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
US11421010B2 (en) * 2016-10-07 2022-08-23 Board Of Regents, The University Of Texas System T cells expressing membrane-anchored IL-12 for the treatment of cancer
AU2018270111B2 (en) * 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3728611A4 (en) * 2017-12-20 2021-09-08 VLP Therapeutics, Inc. ALPHAVIRUS REPLICON PARTICLES

Also Published As

Publication number Publication date
JP2023524055A (ja) 2023-06-08
US20210340567A1 (en) 2021-11-04
EP4143323A1 (en) 2023-03-08
IL297564A (en) 2022-12-01
WO2021221127A1 (en) 2021-11-04
KR20230005883A (ko) 2023-01-10
TW202206448A (zh) 2022-02-16
CA3174651A1 (en) 2021-11-04
MX2022013638A (es) 2023-01-24
CN115552009A (zh) 2022-12-30
AU2021264216A1 (en) 2022-11-10
BR112022021828A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
ECSP17059343A (es) ARNi VARIANTE
CL2021000997A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno.
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CO2018004564A2 (es) Genes de ataxia de friedreich modificados y vectores para terapia génica
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CY1117423T1 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CY1115341T1 (el) Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων
AR110567A1 (es) Conjugados específicos de anticuerpo-principio activo (adcs) con inhibidores de ksp (proteína del hueso de la quinecina)
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
CO2021008995A2 (es) Proteínas de unión multiespecíficas con dominios fab mutantes
PE20200722A1 (es) Metodos de terapia genica del factor viii (fviii)
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
BR112017004393A2 (pt) formulações de anticorpo
AR121961A1 (es) Inmunoterapia con citocina
CL2020002650A1 (es) Enzimas quinureninasa humanas y sus usos
BR112022006842A2 (pt) Construtos de igf2 variante
AR119271A1 (es) Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada
CL2018002900A1 (es) Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos.